ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1575

Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change

Sarit Sekhar Pattanaik1, Ankita Singh 2, Shilpa Venkataraman 3, Ramnath Misra 4, Vinita Agrawal 2 and Amita Aggarwal 5, 1Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, 3Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, 5Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: lupus nephritis and Urinary Biomarkers, Lymphocyturia, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Multiple urinary biomarkers have been described for lupus nephritis, however none has reached the clinic due to either complex methodology or low discriminatory power. Recently, urinary CD4 and CD8 T cells have shown high specificity for active lupus nephritis (LN). Thus we studied whether urinary lymphocyte count by simple staining of sediment or T cell count by flowcytometry can serve as a simple and cheap biomarker.

Methods: Patients with active LN (ALN) defined as renal SLEDAI (rSLEDAI) >4, active lupus without nephritis (ANR) defined as SLEDAI >4, inactive nephritis (IN) defined as rSLEDAI ≤4 and SLEDAI < 4, and age matched healthy controls(HC)were included. Renal biopsy was done if not contraindicated. Lymphocytes in the urine were stained using Kovak stain and reported as number of cells/high power field. CD3 T cells were counted by FACS using anti-CD3 antibody and DAPI for live gate. Immunohistochemistry was done on formalin fixed paraffin blocks of renal biopsy for CD3 and the distribution and number of cells was counted. Statistical analysis was done using SPSSv23.0

Results: Among 74 patients, 44 had ALN (40 females, mean age 30 years and mean SLEDAI:12.9±6.5), 10 had ANR disease (9 females, mean age: 27 years, mean SLEDAI:8.3±3.74)and 20 patients had IN (19 females, mean age: 33 years, mean SLEDAI:0.35±0.74). 10 healthy controls (all females, mean age:26 years) The median(IQR)Lymphocyte count in the urine was 4(7) in ALN as compared to ANR [2(3.5),p=0.1], IN (0, p< 0.001) and HC(0,p< 0.001). The median CD3 count by FACS was 2793(8982) in ALN as compared to ANR [209(539.2), p=0.001],IN [86(303),p< 0.001] and HC [115(195),p< 0.001).There was moderate correlation between lymphocyturia and urinary CD3 count (r=0.59, p< 0.001).
Lymphocyturia had moderate correlation with SLEDAI (r=0.59, p< 0.001), rSLEDAI(r=0.58, p< 0.001). Similarly, urinary CD3 cell count had moderate correlation with SLEDAI (r=0.47,p< 0.001), rSLEDAI (r=0.54, p< 0.001).The ROC curve for lymphocyturia to differentiate ALN from IN (AUC: 0.87) and for CD3 (AUC: 0.874)[Fig 1].
In 15 patients of ALN on follow up, there was a excellent correlation between change in SLEDAI and change in lymphocyte count (r=0.845,p< 0.001).In 31 patients with renal biopsy, there was a moderate correlation between the CD3 cells by IHC in tubulointerstitial compartment and urinary CD3 cells(r=0.55,p=0.001) however there was no relation with glomerular CD3 count

Conclusion: Lymphocyturia measured by simple staining of urinary sediment can be a cheap and effective marker of active LN and can be used to follow up patients with active nephritis in resource poor countries.

Fig 1: ROC curve of lymphocyturia and urinary CD3 cells to differentiate ALN from IN


Disclosure: S. Pattanaik, None; A. Singh, None; S. Venkataraman, None; R. Misra, None; V. Agrawal, None; A. Aggarwal, None.

To cite this abstract in AMA style:

Pattanaik S, Singh A, Venkataraman S, Misra R, Agrawal V, Aggarwal A. Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/lymphocyturia-is-a-good-and-cheap-biomarker-for-active-lupus-nephritis-and-is-sensitive-to-change/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lymphocyturia-is-a-good-and-cheap-biomarker-for-active-lupus-nephritis-and-is-sensitive-to-change/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology